TransAlta Corporation heads into today's Q1 2026 earnings release with a notable pattern of insider selling that has run for weeks — even as short sellers have quietly built positions.
The most striking pre-earnings signal is the one-sided insider activity. Over the 90 days through March, executives collectively offloaded roughly CAD $5.4 million worth of shares on a net basis. The Chief Administration Officer, Jane Nyla Fedoretz, executed no fewer than six separate sell transactions between early March and the end of the month, at prices ranging from CAD $17.45 to $19.13 per share. Two Executive Vice Presidents — Blain Van Melle and Chris Fralick — added further disposals, with Van Melle alone clearing over CAD $780,000 in a single session in early March. None of the recent trades carry a significance score above 3 out of 10, pointing to routine plan-based selling rather than an aggressive directional bet. Still, the consistency of the selling is notable given the stock has since retreated from those prices to CAD $17.45.
Short sellers have been moving in the opposite direction, even if they haven't yet hit extreme levels. Short interest jumped 36% over the past month to 4.6% of the free float — driven by a step-up in mid-April from roughly 12.1 million shares to 13.8 million. Days to cover, at 10.8 per FINRA data, are elevated, reflecting thin average daily volume against that borrowed position. The ORTEX short score has nudged lower recently, from the mid-44s to 42.1, suggesting some easing in bearish conviction near-term — but the month-long build still registers as the more significant trend. Borrowing costs spiked to 2.42% this week, roughly three times the lows seen earlier in April, though that remains an affordable rate overall. Availability is extremely loose, pointing to ample room for additional shorting if the print disappoints.
Analyst sentiment is constructive but dated — the most recent consensus data is from mid-April and falls outside the 14-day freshness window, so specific targets are not cited here. What the ORTEX screening data does show is that the analyst-implied return potential runs to 37%, based on a mean price target of CAD $23.55 versus the current price near $17.45. The EV/EBITDA multiple of 10.2x has drifted higher by roughly 0.2 turns over the past month even as the stock fell 7% in the same period — a valuation creep that bulls may argue reflects improving underlying business value, while bears will point to a PE of 67x as a stretched entry point. The dividend score ranks in the 90th percentile, a consistent draw for income-oriented holders; Brookfield alone holds 11.2% of shares, and the top-15 institutions collectively own more than 55%.
The print will test whether the management team's current operational execution can justify analyst return expectations that sit well above the current price — and whether the month-long rise in short positioning reflects a genuine fundamental concern or simply a macro hedge ahead of a result.
See the live data behind this article on ORTEX.
Open TA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
